Great news. In the Phase 3 INDIGO trial, this targeted drug more than doubled progression-free survival and delayed the need for radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma following surgery. It will likely become standard of care first-line therapy for Grade 2 IDH-mutant glioma. We don't yet know whether it will be helpful for high-grade gliomas (HGG) harboring an IDH mutation, but it's worth a discussion. Many HGG patients with IDH mutations are already trying off-label IDH inhibitors (e.g., ivosidenib/Tibsovo).